Improved Outcomes in Eosinophilic Esophagitis with Higher Medication Possession Ratio

Nathan T. Kolasinski, Eric A. Pasman, Cade M. Nylund, Patrick T. Reeves, Daniel I. Brooks, Katerina G. Lescouflair, Steve B. Min
{"title":"Improved Outcomes in Eosinophilic Esophagitis with Higher Medication Possession Ratio","authors":"Nathan T. Kolasinski, Eric A. Pasman, Cade M. Nylund, Patrick T. Reeves, Daniel I. Brooks, Katerina G. Lescouflair, Steve B. Min","doi":"10.3390/medicines11040008","DOIUrl":null,"url":null,"abstract":"Eosinophilic esophagitis (EoE) disease activity can be caused by treatment non-adherence. Medication possession ratio (MPR) is an established metric of medication adherence. A higher MPR correlates with better outcomes in several chronic diseases, but MPR has not been investigated with respect to EoE. A retrospective cohort study was performed using an established EoE registry for the years 2005 to 2020. Treatment periods were identified, MPRs were calculated, and medical records were assessed for histologic remission (<15 eos/hpf), dysphagia, food impaction, stricture occurrence, and esophageal dilation that corresponded to each treatment period. In total, 275 treatment periods were included for analysis. The MPR in the histologic remission treatment period group was 0.91 (IQR 0.63–1) vs. 0.63 (IQR 0.31–0.95) for the non-remission treatment period group (p < 0.001). The optimal MPR cut-point for histologic remission was 0.7 (Sen 0.66, Spec 0.62, AUC 0.63). With MPRs ≥ 0.7, there were significantly increased odds of histologic remission (odds ratio 3.05, 95% confidence interval 1.79–5.30) and significantly decreased odds of dysphagia (OR 0.27, 95% CI 0.15–0.45), food impaction (OR 0.26, 95% CI 0.11–0.55), stricture occurrence (OR 0.52 95% CI 0.29–0.92), and esophageal dilation (OR 0.29, 95% CI 0.15–0.54). Assessing MPR before repeating an esophagogastroduodenoscopy may decrease unnecessary procedures in the clinical management of eosinophilic esophagitis.","PeriodicalId":18644,"journal":{"name":"Medicines","volume":"106 46","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicines","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/medicines11040008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Eosinophilic esophagitis (EoE) disease activity can be caused by treatment non-adherence. Medication possession ratio (MPR) is an established metric of medication adherence. A higher MPR correlates with better outcomes in several chronic diseases, but MPR has not been investigated with respect to EoE. A retrospective cohort study was performed using an established EoE registry for the years 2005 to 2020. Treatment periods were identified, MPRs were calculated, and medical records were assessed for histologic remission (<15 eos/hpf), dysphagia, food impaction, stricture occurrence, and esophageal dilation that corresponded to each treatment period. In total, 275 treatment periods were included for analysis. The MPR in the histologic remission treatment period group was 0.91 (IQR 0.63–1) vs. 0.63 (IQR 0.31–0.95) for the non-remission treatment period group (p < 0.001). The optimal MPR cut-point for histologic remission was 0.7 (Sen 0.66, Spec 0.62, AUC 0.63). With MPRs ≥ 0.7, there were significantly increased odds of histologic remission (odds ratio 3.05, 95% confidence interval 1.79–5.30) and significantly decreased odds of dysphagia (OR 0.27, 95% CI 0.15–0.45), food impaction (OR 0.26, 95% CI 0.11–0.55), stricture occurrence (OR 0.52 95% CI 0.29–0.92), and esophageal dilation (OR 0.29, 95% CI 0.15–0.54). Assessing MPR before repeating an esophagogastroduodenoscopy may decrease unnecessary procedures in the clinical management of eosinophilic esophagitis.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
提高嗜酸性粒细胞食管炎患者的药物拥有率可改善疗效
嗜酸性粒细胞食管炎(EoE)疾病的活动性可由不坚持治疗引起。药物持有率(MPR)是衡量用药依从性的既定指标。在多种慢性疾病中,较高的持药率与较好的治疗效果相关,但尚未对食管炎的持药率进行调查。一项回顾性队列研究利用已建立的胃食管返流登记系统对 2005 年至 2020 年的胃食管返流进行了研究。研究人员确定了各治疗期,计算了 MPR,并评估了与各治疗期相对应的组织学缓解(<15 eos/hpf)、吞咽困难、食物嵌塞、狭窄发生和食管扩张的病历。总共有 275 个治疗期被纳入分析。组织学缓解治疗期组的 MPR 为 0.91(IQR 0.63-1),而非缓解治疗期组的 MPR 为 0.63(IQR 0.31-0.95)(P < 0.001)。组织学缓解的最佳 MPR 切点为 0.7(Sen 0.66,Spec 0.62,AUC 0.63)。当 MPR≥ 0.7 时,组织学缓解的几率明显增加(几率比 3.05,95% 置信区间 1.79-5.30),吞咽困难(OR 0.27,95% CI 0.15-0.45)、食物嵌塞(OR 0.26,95% CI 0.11-0.55)、狭窄发生(OR 0.52 95% CI 0.29-0.92)和食管扩张(OR 0.29,95% CI 0.15-0.54)的几率明显降低。在重复食管胃十二指肠镜检查之前评估 MPR,可减少嗜酸性粒细胞性食管炎临床治疗中不必要的程序。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Postoperative Nausea and Vomiting in the Ambulatory Surgery Center: A Narrative Review An Unusual Case of Immune Complex-Mediated Membranoproliferative Glomerulonephritis as Renal Manifestation of Idiopathic Hypereosinophilic Syndrome: A Case Report and Literature Review Medicines—Aims and Scope Updates Human Leucocyte Antigen Genetics in Idiosyncratic Drug-Induced Liver Injury with Evidence Based on the Roussel Uclaf Causality Assessment Method. Improved Outcomes in Eosinophilic Esophagitis with Higher Medication Possession Ratio
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1